EBITDA increased 28.8% to ₹32.8 crore in the March quarter, compared with ₹25.5 crore in the corresponding period last year. EBITDA margin stood at 18.6% in the quarter, compared with 17.8% in the year-ago period.
The domestic formulations business posted 18.2% growth in Q4 FY26, compared with 10.1% growth in the Indian Pharma Market. The company said this was 1.8 times the market growth. The API division reported 144.3% growth in Q4 FY26 after operations resumed at the unit.Also Read: RPG Life targets ₹100 crore sales from pain relief drug Naprosyn over the next two years
For FY26, revenue from operations grew 8.3%. The company reported an EBITDA margin of 24.4% for the full year. Domestic formulations, which contributed 70% of overall sales, grew 13.7% in FY26 compared with 8.6% growth in the Indian Pharma Market. The company said growth was led by nephrology, oncology and pain management.The board has recommended a final dividend of ₹24 per equity share of face value ₹8 each, or 300% of face value, for FY26, subject to shareholder approval.
Ashok Nair, Managing Director, RPG Life Sciences Ltd, said, “Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations.
Also Read: RPG Life Sciences Q2 net profit jumps to ₹37 crore, revenue up 6%
Looking ahead, we intend to strengthen our new product pipeline, sharpen the equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets.”
Shares of RPG Life Sciences Ltd ended at ₹2,024.05, down by ₹34.70, or 1.69%, on the BSE.
First Published: Apr 29, 2026 10:33 PM IS
